Legrand Fanny, Klion Amy D
Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):167-74. doi: 10.1016/j.jaip.2015.01.013.
The recent explosion in the number of biologic therapies in clinical development for the treatment of eosinophilic disorders is unprecedented. As these agents become available for clinical use, the selection of the most appropriate agent for a given patient will become increasingly complicated. The aims of this review were 2-fold: (1) to present the lessons learned from clinical trials using the first generation of eosinophil-targeted biologics (anti-IL-5 antibodies) and (2) to discuss the advantages and potential limitations of currently available and novel targeted therapies to treat eosinophilic disorders.
目前用于治疗嗜酸性粒细胞疾病的生物疗法在临床开发中的数量激增，这是前所未有的。随着这些药物可供临床使用，为特定患者选择最合适的药物将变得越来越复杂。本综述的目的有两个：（1）介绍使用第一代嗜酸性粒细胞靶向生物制剂（抗IL-5抗体）的临床试验所吸取的经验教训；（2）讨论目前可用的和新型靶向疗法治疗嗜酸性粒细胞疾病的优势和潜在局限性。
